The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Feb 2020
Multicenter StudyCemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Cemiplimab has shown substantial antitumour activity in patients with metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous squamous cell carcinoma have poor prognosis with conventional systemic therapy. We present a primary analysis of the safety and antitumour activity of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma. ⋯ Regeneron Pharmaceuticals and Sanofi.